- » GOLDEN HELIX BLOG
- » FLICKR
- » homepage
Past symposia GoldenHelix Symposia
OCTOBER 15, 2009
Divani Apollon Palace & Spa, Athens Greece.
“Pharmacogenomics: Paving the path to personalized medicine”.
INTRODUCTION
George Patrinos (Greece) Translation of genetic knowledge into clinical practice: The expectations and realities of personalized medicines
Federico Innocenti (USA) Pharmacogenomics: an Odyssey
Laura Hodges (USA) PharmGKB: The Pharmacogenomics Knowledge base
Session 2
TRANSLATION OF PHARMACOGENOMICS INTO CLINICAL PRACTICE: THE WARFARIN PARADIGM
Allan Rettie (USA) Pharmacogenetics of vitamin K antagonists and resistance to anticoagulants
Panos Deloukas (United Kingdom) A whole genome scan for polymorphisms influencing warfarin dosing
Farhad Kamali (United Kingdom) The International Warfarin Pharmacogenetics consortium
Anders Rane (Sweden) Warfarin pharmacogenomics - Translation into clinical practice
1st Keynote lecture
Michel Eichelbaum (Germany) Pharmacogenomic-guided drug therapy: Where do we stand in 2009
OCTOBER 16, 2009
Session 3
CANCER PHARMACOGENOMICS
Rafal Dziadziuszko (Poland) Response to EGFR inhibitors: A paradigm for integrating germ-line and somatic molecular determinants
Ron van Shaik (the Netherlands) Gene variants in tamoxifen metabolizing enzymes CYP2D6 and CYP2C19 predict breast cancer endocrine therapy outcome
Sharon Marsh (USA) Irinotecan pharmacogenomics
David Josephy (CA) Polymorphisms of glutathione transferase genes and enzymes: implications for cancer risk and cancer treatment
Federico Innocenti (USA) Early experience with genome-wide association studies in cancer chemotherapy
Session 4
PHARMACOGENOMICS IN NEUROPSYCHIATRIC DISEASES
Maria Arranz (United Kingdom) Pharmacogenetics and critical candidate genes involved in drug response for schizophrenia
Sefi Kronenberg (Israel) Pharmacogenomics of anti-depressants
Norman Delanty (Ireland) Pharmacogenomics for epilepsy treatment
Alessio Squassina (Italy) Pharmacogenomics of the response to mood stabilizers in bipolar disease
2nd Keynote lecture
Lawrence Lesko (USA) Level of evidence to validate pharmacogenetic biomarkers
OCTOBER 17, 2009
Session 5
PHARMACOGENOMICS OF OTHER DISEASES
George Patrinos (Greece) Pharmacogenomics of hemoglobinopathies
Maria-Luisa Brandi (Italy) Pharmacogenomics of bone treatments
Eric Thervet (France) Impact of heritable genetic variability on renal transplantation
Mikko Niemi (Finland) Statin pharmacogenomics for cardiovascular patients
Vassilis Vassiliou (USA) Pharmacogenomics: Aldehyde Dehydrogenases in human disease
Session 6
ADVERSE DRUG REACTIONS
Al Jorgensen (United Kingdom) Risk modeling strategies for pharmacogenetic studies
Mara Becker (USA) Identifying genomic causes of Adverse Drug Reactions in children
Divani Apollon Palace & Spa, Athens Greece.
“Pharmacogenomics: Paving the path to personalized medicine”.
INTRODUCTION
George Patrinos (Greece) Translation of genetic knowledge into clinical practice: The expectations and realities of personalized medicines
Federico Innocenti (USA) Pharmacogenomics: an Odyssey
Laura Hodges (USA) PharmGKB: The Pharmacogenomics Knowledge base
Session 2
TRANSLATION OF PHARMACOGENOMICS INTO CLINICAL PRACTICE: THE WARFARIN PARADIGM
Allan Rettie (USA) Pharmacogenetics of vitamin K antagonists and resistance to anticoagulants
Panos Deloukas (United Kingdom) A whole genome scan for polymorphisms influencing warfarin dosing
Farhad Kamali (United Kingdom) The International Warfarin Pharmacogenetics consortium
Anders Rane (Sweden) Warfarin pharmacogenomics - Translation into clinical practice
1st Keynote lecture
Michel Eichelbaum (Germany) Pharmacogenomic-guided drug therapy: Where do we stand in 2009
OCTOBER 16, 2009
Session 3
CANCER PHARMACOGENOMICS
Rafal Dziadziuszko (Poland) Response to EGFR inhibitors: A paradigm for integrating germ-line and somatic molecular determinants
Ron van Shaik (the Netherlands) Gene variants in tamoxifen metabolizing enzymes CYP2D6 and CYP2C19 predict breast cancer endocrine therapy outcome
Sharon Marsh (USA) Irinotecan pharmacogenomics
David Josephy (CA) Polymorphisms of glutathione transferase genes and enzymes: implications for cancer risk and cancer treatment
Federico Innocenti (USA) Early experience with genome-wide association studies in cancer chemotherapy
Session 4
PHARMACOGENOMICS IN NEUROPSYCHIATRIC DISEASES
Maria Arranz (United Kingdom) Pharmacogenetics and critical candidate genes involved in drug response for schizophrenia
Sefi Kronenberg (Israel) Pharmacogenomics of anti-depressants
Norman Delanty (Ireland) Pharmacogenomics for epilepsy treatment
Alessio Squassina (Italy) Pharmacogenomics of the response to mood stabilizers in bipolar disease
2nd Keynote lecture
Lawrence Lesko (USA) Level of evidence to validate pharmacogenetic biomarkers
OCTOBER 17, 2009
Session 5
PHARMACOGENOMICS OF OTHER DISEASES
George Patrinos (Greece) Pharmacogenomics of hemoglobinopathies
Maria-Luisa Brandi (Italy) Pharmacogenomics of bone treatments
Eric Thervet (France) Impact of heritable genetic variability on renal transplantation
Mikko Niemi (Finland) Statin pharmacogenomics for cardiovascular patients
Vassilis Vassiliou (USA) Pharmacogenomics: Aldehyde Dehydrogenases in human disease
Session 6
ADVERSE DRUG REACTIONS
Al Jorgensen (United Kingdom) Risk modeling strategies for pharmacogenetic studies
Mara Becker (USA) Identifying genomic causes of Adverse Drug Reactions in children
Related file downloads:
